# Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment

> **NCT01072812** · PHASE1 · TERMINATED · sponsor: **Annovis Bio Inc.** · enrollment: 5 (actual)

## Conditions studied

- Alzheimer's Disease
- Amnestic Mild Cognitive Impairment

## Interventions

- **DRUG:** Posiphen® tartrate capsules

## Key facts

- **NCT ID:** NCT01072812
- **Lead sponsor:** Annovis Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-02
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Business decision based on funding
- **Last updated:** 2015-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01072812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01072812, "Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01072812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*